

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO. 10/533,693

Peter Vanderslice TEX4542P0481US

INTERNATIONAL APPLICATION NO.

PCT/US03/35526


I.A. FILING DATE

PRIORITY DATE

11/07/2003

11/08/2002

32116 WOOD, PHILLIPS, KATZ, CLARK & MORTIMER 500 W. MADISON STREET **SUITE 3800** CHICAGO, IL 60661



CONFIRMATION NO. 6132 371 FORMALITIES LETTER *OC000000017938853*

Date Mailed: 01/30/2006

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Priority Document
- Copy of the International Application filed on 05/03/2005
- Copy of the International Search Report filed on 05/03/2005
- Copy of IPE Report filed on 05/03/2005
- Preliminary Amendments filed on 05/03/2005
- Information Disclosure Statements filed on 05/03/2005
- Oath or Declaration filed on 12/14/2005
- Request for Immediate Examination filed on 05/03/2005
- U.S. Basic National Fees filed on 05/03/2005
- Priority Documents filed on 05/03/2005
- Power of Attorney filed on 05/03/2005
- Specification filed on 05/03/2005
- Claims filed on 05/03/2005
- Abstracts filed on 05/03/2005

Applicant's response filed 12/14/2005 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 11/23/2005 have not been completed.

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(q), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19,

2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/533,693	PCT/US03/35526	TEX4542P0481US

FORM PCT/DO/EO/916 (371 Formalities Notice)

#

RESPONSE TO NOTICE TO NOTIFICATION OF DEFECTIVE Docket No.: TEX4542P0481US **RESPONSE** Peter Vanderslice et a. Confirmation No.: 6132 Applicant(s): 05/03/2005 Serial No .: 10/533,693 Filing Date: Examiner: Unknown Group Art Unit: Unknown Combination Products with Carboxylic Acid Derivatives that Inhibit the binding of Invention:

Integrins to their Receptors and Other Therapeutic Compounds

Mail Stop Missing Parts Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith in response to the Formalities Letter dated <u>01/30/2006</u> are:

- \Box Executed declaration or oath for this application.
- Return copy of the Notice of Defective Response of Application.
- Other: Return Postcard; Amendment; a Sequence Listing; CD w/ Sequence Listing in Computer Readable format; Statement regarding the content of the CDs is identical to the written sequence listing and an Associate Power of Attorney
- \square A check in the amount of N/A to cover the filing fee and/or surcharge.
- The Commissioner is hereby authorized to charge any additional fees which may be required to this application under 37 C.F.R. §1.15-§1.17, or credit any overpayment, to Deposit Account No. 23-0785. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Mark V. Polyakov, Reg. No.

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER Citicorp Center, Suite 3800 500 West Madison Street Chicago, Illinois 60661-2511 312/876-1800

CERTIFICATE OF MAILING

I hereby certify that this document is being deposited with the United States Postal Service with sufficient postage at First Class Mail in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on **February 24, 2006**.

Stephanie Frain



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

olicant: Peter Vanderslice et al.

Serial No.: 10/533,693

Filed: May 3, 2005

For:

Combination Products with Carboxylic Acid

Derivatives that Inhibit the Binding of Integrins to their Receptors and Other

Therapeutic Compounds

Attorney Docket No.: TEX4542P0481US

Examiner: Unknown

Group Art Unit: Unknown

Certificat f Mailing:

I hereby certify that this paper (along with any paper ref rred to as being attached or enclosed) is being sent by first class mail to Mail Stop Missing Parts,

Commissioner for Patents, PO Box 1450.

Alexandria, VA 22313-1450 on February 24, 2006.

iphanie Franc

Commissioner For Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

> STATEMENT TO SUPPORT FILINGS AND SUBMISSIONS IN ACCORDANCE WITH 37 C.F.R. §1.821 THROUGH §1.825

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The undersigned, being the attorney of record of the above-identified patent application, submits the following statement regarding the Sequence Listing in paper and computer readable form submitted herewith:

> I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted herewith in accordance with C.F.R. §1.821(c) and (e), respectively, are the same.

The Commissioner is hereby authorized to charge any additional fees which may be required in connection with this submission to Deposit Account No. 23-0785.

Respectfully submitted,

By

Pølyakoy, Reg. Attorney for Applicants

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER 500 West Madison Street, Suite 3800

Chicago, Illinois 60661-2511

312/876-1800

February 24, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peter Vanderslice et al.

Serial No.: 10/533,693

Filed: May 3, 2005

For:

Combination Products with Carboxylic Acid Derivatives that Inhibit the Binding of Integrins to their Receptors and Other

Therapeutic Compounds

Attorney Docket No.: TEX4542P0481US

Examiner: Unknown

Group Art Unit: Unknown

Certificate of Mailing:

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being sent by first class mail to Mail Stop Missing Parts, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on February 24, 2006.

Alexandria, VA 22313-1450 on February 24, 2

AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

This Amendment is being submitted in connection with the Notification of Defective Response mailed on January 30, 2006 in the above-identified application. Also enclosed herewith is a Sequence Listing as required by 37 CFR 1.821(c), a copy of the Sequence Listing in computer readable form and a Statement to Support Filings and Submissions in Accordance with 37 C.F.R §1.821 through §1.825.

Please amend the above-referenced application after the abstract to include one page of the Sequence Listing included herewith. If any additional fees are required as a result of the filing of this paper, the Commissioner is hereby authorized to charge to Deposit Account No. 23-0785 any such fees.

Respectfully submitted,

Mark V. Polyakov

Registration No. 54,377

Attorney for Applicants

Wood, Phillips, Katz, Clark & Mortimer 500 West Madison Street Suite 3800 Chicago, IL 60661

Tel.: (312) 876-2103 Fax.: (312) 876-2020

February 24, 2006

2